Thomas Miller
Keine laufenden Positionen mehr
Profil
Thomas B.
Miller worked as a Finance Director & Controller at CoCensys, Inc. from 1997 to 1999.
He then worked as a Controller-Financial Operations at Emulex Corp.
After that, he worked at Ixia for 14 years as the Chief Financial Officer & Head-Investor Relations.
From 2014 to 2017, he worked as the Chief Financial Officer at Second Sight Medical Products, Inc. He also held the position of Chief Financial Officer at Second Sight Medical Products, Inc. Mr. Miller has an MBA from the University of Southern California and an undergraduate degree from the University of California, Berkeley.
Ehemalige bekannte Positionen von Thomas Miller
| Unternehmen | Position | Ende |
|---|---|---|
| SECOND SIGHT MEDICAL PRODUCTS | Finanzdirektor/CFO | 22.03.2018 |
| SECOND SIGHT MEDICAL PRODUCTS | Finanzdirektor/CFO | 30.06.2017 |
| IXIA | Finanzdirektor/CFO | 03.03.2014 |
CoCensys, Inc.
 CoCensys, Inc. Pharmaceuticals: MajorHealth Technology CoCensys, Inc. discovers and develops drugs to treat neurological and psychiatric disorders. The company's product development programs focus on two novel and proprietary classes of compounds: Epalons, to treat epilepsy, migraine, anxiety and sleep disorders and Excitatory Amino Acid (EAA) receptor antagonists, to treat stroke, head trauma, epilepsy and Parkinson's disease. The company was founded in 1989 and is located in Irvine, CA. | Finanzdirektor/CFO | 01.10.1999 |
| EMULEX CORPORATION | Corporate Officer/Principal | - |
Ausbildung von Thomas Miller
| University of California, Berkeley | Undergraduate Degree |
| University of Southern California | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Ixia
 Ixia Information Technology ServicesTechnology Services Ixia provides multi-port network performance analysis services. The firm’s products and services include test applications, security products, visibility products, cloud, performance monitoring, test hardware, training, testing as a service and test consulting. It offers architecture, technologies and segments. The company was founded by Errol Ginsberg and Jean-Claude Asscher in May 1997 and is headquartered in Calabasas, CA. | Technology Services |
Emulex Corp.
 Emulex Corp. Computer CommunicationsElectronic Technology Emulex Corp. provides hardware and software solutions for global networks that support enterprise, cloud, government, and telecommunications. The firm operates through two business segments: Networking and Visibility Segment. The Networking Segment includes network connectivity products (NCP), storage connectivity products (SCP), and advanced technology and other products. Its SCP include InSpeed, switch-on-a-chip or backend connectivity, bridge, and router products; and the advanced technology and other products consists of its pilot integrated baseboard management controllers and other products and services. The company was founded by Fred B. Cox on February 15, 1979 and is headquartered in San Jose, CA. | Electronic Technology |
CoCensys, Inc.
CoCensys, Inc. Pharmaceuticals: MajorHealth Technology CoCensys, Inc. discovers and develops drugs to treat neurological and psychiatric disorders. The company's product development programs focus on two novel and proprietary classes of compounds: Epalons, to treat epilepsy, migraine, anxiety and sleep disorders and Excitatory Amino Acid (EAA) receptor antagonists, to treat stroke, head trauma, epilepsy and Parkinson's disease. The company was founded in 1989 and is located in Irvine, CA. | Health Technology |
Second Sight Medical Products, Inc.
 Second Sight Medical Products, Inc. Medical SpecialtiesHealth Technology Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It offers Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device intended to provide artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA. | Health Technology |
